Australian Clinical Labs Ltd (acl) Logo

Australian Clinical Labs Ltd (ACL)

___:___ · Healthcare
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE

ACL Chart

Snapshot

ACL's Principal Activity is the provision of pathology services.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2021 YTD
1 Year
vs Sector (1yr) -
vs ASX 200 (1yr) -16.68%

Size

Market Capitalisation
ASX Rank 345 of 2,319
Sector Rank 21 of 199

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies OCA / API / IDX
EPS $0.00
DPS $0.00
NTA per share $0.00

Broker Consensus

ACL is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Announcements

Date Heading Pages File Size Time

Corporate Overview

Australian Clinical Labs Limited (ACL) is a private provider of pathology services in Australia. ACL's mission is to combine talented people, medical and scientific leadership, with innovative thinking and technologies to empower decision making that saves and improves patients' lives. It is servicing over 90 private and public hospitals.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Clayton VIC 3168
Website www.clinicallabs.com.au
Registry Link Market Services
Auditor Pitcher Partners
Date Listed 14 May 2021

Upcoming Calendar (Forecasted)

Date Event
25/08/2022 Report (Prelim)
23/09/2022 Report (Annual)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Dr Michael Philip Stanford Non-Executive Director Apr 2021 Director Bio icon

Dr Michael Philip Stanford

Non-Executive Director

Dr Stanford has over 25 years of Non-Executive Director experience across a range of industries including healthcare services, diagnostics, biotech, pharmaceutical, property, aged care and higher education. Michael is the current Chair of Diabetes Australia, an Independent Non-Executive Director of NorthWest Healthcare Property Management Limited and Nucleus Network Limited, and a Senior Advisor at Medibank Private Limited. Michael's former roles include Non-Executive Director for ACL between 2016 and 2019, Healthscope Limited, Virtus Health Limited, and Deputy Chancellor of Curtin University. He was in Group Chief Executive Officer roles for 23 years including 16 years at St John of God Health Care. He was also formerly a specialist in public health medicine.

Dr Leanne Rowe Non-Executive Director Apr 2021 Director Bio icon

Dr Leanne Rowe

Non-Executive Director

Dr Rowe has over 30 years of clinical experience in the public and private health systems across acute care, aged care, mental health and community health. Leanne is currently Chair of Nexus Hospitals and a Non-Executive Director of Japara Healthcare Limited, Doctor Care Anywhere Group PLC, the Medical Indemnity Protection Society and MIPS Insurance. Previously she was Chair of the Royal Australian College of General Practitioners and a Non-Executive Director of Medibank Private, I-MED Radiology Network, GMHBA, Australian Health Management, Barwon Health and Beyond Blue. Leanne is a former Deputy Chancellor of Monash University.

Mr Andrew Mark Rendle Dutton Non-Executive Director Apr 2021 Director Bio icon

Mr Andrew Mark Rendle Dutton

Non-Executive Director

Mr Dutton has 30 years of management, business development and technology experience across Australia, Asia and Europe. Andrew is the current Chair of Land Registry Services and was recently an Advisor to FinancialForce APJ. He has had Chief Executive Officer and Board experience globally and within Australia. Andrew's former roles include Chair of NVOI Pty Ltd and SAI Global Pty Ltd; Chief Executive Officer at Land Registry Services and Integrated Research Limited; Managing Director of the Asia Pacific/Japan region for VMware Inc.; and senior executive positions at IBM, Computer Associates, BEA Systems Inc., Lend Lease and Norwich Union Financial Services Group including roles as CFO, CMO, CRO and Divisional Heads. At IBM, Andrew was elected to the Worldwide Senior Leadership Team.

Mr Mark Haberlin Non-Executive Director Apr 2021 Director Bio icon

Mr Mark Haberlin

Non-Executive Director

Mr Haberlin has over 25 years of audit, risk management, capital transactions and mergers and acquisitions experience across industries including healthcare, real estate and financial services. Mark is the Lead Independent Director and Chair of the Audit & Risk Committee of Abacus Property Group. Mark is also an Independent Non-Executive Director and the Chair of the Audit & Risk Committee of Laybuy Group Limited. Previously, Mark was the Chair of PwC Australia and PwC's Public Reporting Panel, as well as a Director of the European Australia Business Council and PwC Asia Pacific.

Mr Michael Thomas Alscher Non-Executive Chairman,Non-Executive Director Dec 2020 Director Bio icon

Mr Michael Thomas Alscher

Non-Executive Chairman,Non-Executive Director

Mr Alscher is the Managing Partner and founder of Crescent, an Australian private equity investment firm, focusing on high growth companies and certain industry sectors such as healthcare. Michael is the current Chair of Cardno Limited, National Dental Care Limited, National Home Doctor Service Pty Ltd and is a Non-Executive Director of Clearview Wealth Limited. Michael's former director roles include Chair of Cover-More Group Limited, LifeHealthcare Group Limited and Director of Metro Performance Glass Limited. Prior to founding Crescent in 2000, Michael was a strategy consultant at Bain International and LEK Partnership as well as holding several senior operating roles.

Mr Nathanial Jonothan Thomson Non-Executive Director Dec 2020 Director Bio icon

Mr Nathanial Jonothan Thomson

Non-Executive Director

Mr Thomson is a Partner at Crescent, an Australian private equity investment firm. Nathanial has over 20 years of experience in strategy consulting, private equity and investment banking. He has consulting experience from his prior role at McKinsey & Co. Nathanial is a current Director of Cardno Limited, National Dental Care Limited, Clearview Wealth Limited and National Home Doctor Service Pty Ltd. Nathanial's former director roles include Deputy Chair of Cover-More Group Limited and a Non-Executive Director of Metro Performance Glass Limited.

Ms Melinda Leigh McGrath Chief Executive Officer,Executive Director Dec 2020 Director Bio icon

Ms Melinda Leigh McGrath

Chief Executive Officer,Executive Director

Ms McGrath has more than 30 years' experience in healthcare with over 20 years of experience in chief executive roles and over 13 years of experience in pathology CEO roles. Melinda has been involved in the organisation's transformation, building ACL's scale and operational performance improvement over the past six years, overseeing the integration of Healthscope's Australian pathology business, St John of God Health Care's pathology business, Perth Pathology and SunDoctors. Melinda was Chief Executive Officer of QML Pathology (part of Healius) from 2008 to 2015, where she developed five QML brands and established Tasmania Medical Laboratories. Prior to that, Melinda held various chief executive roles at private regional and tertiary referral hospitals in Queensland including The Sunshine Coast Private Hospital, St Andrew's War Memorial Hospital and St Stephens Private Hospital. Melinda has held board member positions at Metro North Hospitals and Health Service including Royal Brisbane, Prince Charles, Redcliffe, Caboolture and related health services, and a superannuation fund, UC Super.

Ms Eleanor Padman Company Secretary N/A

Director Transactions

ACL directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
25/05/21 Melinda McGrath Issued 247,252 $3.64 $899,997 Issue of securities

Director Interests

The current holdings of ACL directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Mark Haberlin 28/04/2021 N/A 25,000 N/A N/A
Andrew Dutton 28/04/2021 N/A 80,000 N/A N/A
Leanne Rowe 28/04/2021 N/A 37,500 N/A N/A
Michael Stanford 28/04/2021 20,000 10,000 N/A N/A
Melinda McGrath 19/12/2020 2,123,508 667,965 N/A N/A
Nathanial Thomson 19/12/2020 0 N/A N/A N/A
Michael Alscher 19/12/2020 N/A 250,000 N/A N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on May 14, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Crescent Capital Partners V, LP. 40,385,443 20.00%
HSBC Custody Nominees (Australia) Limited 23,617,578 11.70%
National Australia Bank Limited 18,842,542 9.30%
Instanz Nominees Pty Ltd 14,036,045 7.00%
CCP Trusco 1 Pty Ltd 12,383,350 6.10%
Citicorp Nominees Pty Ltd 11,633,833 5.80%
UBS Nominees Pty Ltd 8,501,273 4.20%
BNP Paribas Securities Services 6,562,703 3.30%
CCP Trusco 5 Pty Ltd 6,207,125 3.10%
Morgan Stanley Australia Securities Limited 5,841,216 2.90%
CCP Trusco 4 Pty Ltd 5,533,472 2.70%
CCP Trusco 2 Pty Ltd 5,426,246 2.70%
Credit Suisse Equities (Australia) Limited 5,150,000 2.60%
J.P. Morgan Nominees Australia Pty Limited 4,800,587 2.40%
Perpetual Corporate Trust Limited (i) 3,074,742 1.50%
Perpetual Corporate Trust Limited (ii) 2,635,495 1.30%
Melinda McGrath 2,123,508 1.10%
Merrill Lynch (Australia) Nominees Pty Limited 1,250,000 0.60%
Anthony Landgren 838,211 0.40%
Anthony Friedli 754,390 0.40%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 800 710 345 292 69 2,216

Substantial Shareholders

No Substantial Shareholders for ACL in our database.

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
02-07-21 Ethical Partners Funds Management Pty Ltd 5,800,142 5.75 8.62
19-05-21 Ethical Partners Funds Management Pty Ltd 11,598,277 -- 5.75
14-05-21 ACL SaleCo Limited 49,346,290 -- 33.49
14-05-21 Crescent Capital Partners Management Pty Limited 134,292,481 -- 91.15

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Date Name Sold Previous % New %
19-05-21 ACL SaleCo Limited 49,346,290 33.5 --
18-05-21 Crescent Capital Partners Management Pty Limited 44,610,563 91.2 44.4

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
No Financial Year End data available
Page Icon
ACL Historical Price Data (CSV)
Up to 20 years of EOD share price history
Lock Icon
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.